Fundz

Who to call at bit.bio, and when

Fundz watches for the moments bit.bio starts buying, and tells you who to reach.

  • An alert the day bit.bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at bit.bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at bit.bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

UK cell therapy biotech bit.bio pivots to tool development, forms partnership with BlueRock Therapeutics

Mar 19, 2025

Contract Type

partnership

CambridgeshireInformation TechnologyFinancial ServicesSoftwareScience And EngineeringPayments

Description

UK cell therapy biotech bit.bio has laid off 25% of its staff and shifted focus to biomedical tools over drug development. The company is partnering with Bayer’s BlueRock Therapeutics to develop ioCells, human cells programmed from induced pluripotent stem cells, to reduce variance and timelines for researchers.

Quick answer

UK cell therapy biotech bit.bio pivots to tool development, forms partnership with BlueRock Therapeutics (March 19, 2025). bit.bio is based in Cambridgeshire, England, United Kingdom.

What agreement did bit.bio announce on March 19, 2025?
UK cell therapy biotech bit.bio has laid off 25% of its staff and shifted focus to biomedical tools over drug development. The company is partnering with Bayer’s BlueRock Therapeutics to develop ioCells, human cells programmed from induced pluripotent stem cells, to reduce variance and timelines for researchers.
What does bit.bio do?
bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures.
Where is bit.bio based?
bit.bio is based in Cambridgeshire, England, United Kingdom.

Source: Fundz verified event record.

Company Information

Company

bit.bio

Location

Cambridgeshire, England, United Kingdom

About

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey.

Related People

Abbey
Likely contact at this company
••••••••@••••••••

See Abbey's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for bit.bio's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

bit.bio signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.